[ad_1]
After the vaccine hype: BioNTech will make much less gross sales and income in 2022 – BioNTech shares are within the crimson.
The vaccine producer BioNTech as soon as once more made billions in income final yr. In view of the declining income from the corona vaccine, the event of therapies in opposition to most cancers, for instance, is now to be pushed additional. The proceeds from Mainz amounted to a complete of 17.3 billion euros in 2022 after virtually 19 billion within the earlier yr, as the corporate introduced on Monday. The underside line is that BioNTech posted a web revenue of 9.4 billion euros, additionally barely lower than 2021 with 10.3 billion. For 2023, the corporate expects gross sales of round 5 billion euros with Covid-19 vaccines.
In 2021, BioNTech and the US companion Pfizer had delivered greater than 2.6 billion corona vaccine doses, final yr solely round 2 billion doses have been invoiced. Along with corona vaccines, BioNTech focuses, amongst different issues, on researching approaches in immunotherapy based mostly on the messenger molecule mRNA within the battle in opposition to infectious and autoimmune ailments in addition to most cancers. For future oncology merchandise, the Mainz-based firm wish to arrange a gross sales group within the USA, the EU and different chosen areas this yr and subsequent.
General, the corporate is planning investments in analysis and improvement of two.4 to 2.6 billion euros in 2023. One other a part of the billions in revenue is to move into one other share buyback program. The corporate’s administration wish to have a corresponding program accepted within the quantity of as much as 0.5 billion euros for the interval as much as the top of 2023.
In US buying and selling on the NASDAQ, BioNTech shares are quickly down 3.34 % at $123.92.56.
[ad_2]
Source link
